drugset / Trial / NCT05113966
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This was a Phase 2, multicenter, open-label, single-arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in participants with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received at least 2 prior treatments, at least 1 in the metastatic setting.
Timeline
- Start
- 2021-12-08
- Primary completion
- 2023-11-10
- Completion
- 2024-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | — | Intravenous |
| Background | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |